Q1 2024 Aquestive Therapeutics Inc Earnings Call Transcript
Key Points
- Aquestive Therapeutics Inc (AQST) announced positive Phase 3 results and a positive FDA interaction for Anaphylm, their lead product candidate.
- Aquestive Therapeutics Inc (AQST) successfully raised over $75 million in new capital from high-quality investors.
- FDA approval was received for Libervant diazepam buccal film for treating seizure clusters in patients aged two to five years.
- Aquestive Therapeutics Inc (AQST) is progressing towards the NDA filing for Anaphylm, expecting to complete necessary studies by the end of the third quarter.
- The company has begun typical launch activities for Anaphylm, including packaging design, marketing materials, and sales force planning.
- Aquestive Therapeutics Inc (AQST) faces a complex and competitive pharmaceutical distribution landscape, which requires significant preparation and innovation.
- The company is still in the process of determining the optimal distribution model for Anaphylm, which involves navigating complex payer and market access landscapes.
- Research and development expenses increased significantly, from $3.5 million in Q1 2023 to $5.9 million in Q1 2024, primarily due to the ongoing development of the Anaphylm program.
- Selling, general, and administrative expenses also saw a substantial increase from $7.5 million in Q1 2023 to $10.7 million in Q1 2024.
- Aquestive Therapeutics Inc (AQST) reported a net loss of $12.8 million for Q1 2024, compared to a net income of $8.1 million in Q1 2023.
Good morning and welcome to the Aquestive Therapeutics first-quarter 2024 conference call. (Operator Instructions) As a reminder, this call will be recorded. I would now like to introduce your host for today's conference call, Bennett Watson of ICR Westwicke, Investor Relations. You may begin.
Thank you, operator. Good morning, and welcome to today's call. On today's call, I'm joined by Dan Barber, Chief Executive Officer; and Ernie Toth, Chief Financial Officer, who are going to provide an overview of recent business developments and performance for the first-quarter 2024, followed by a Q&A session. During the Q&A session, the team will be joined by Dr. Stephen Wargacki, Chief Science Officer.
As a reminder, the company's remarks today correspond with the earnings release that was issued after market close yesterday. In addition, a recording of today's call will be made available on Aquestive's website within the Investors section shortly following the conclusion of this call.
To remind you, the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
